This finding corroborates studies that have shown that, at least in adult patients with rheumatoid arthritis, therapies with anti-TNF antibody, a common treatment for severe forms of the disease, induce significant increases in type I IFN response gene activity [31]. The gene discussed is TNF; the disease is rheumatoid arthritis.